For several of the investigated genes (e.g. TP53, PTEN, EGFR, KRAS, ERBB2) the observed mutation patterns and frequencies in our Swedish cohort agree with previous reports on clinical patient cohorts (predominantly comprising of advanced cancers) of similar ethnicity and/or geographic origin (Scandinavia) [19–25], but also with cohorts consisting of selected non-consecutive patients with operable disease [26, 27]. Here, KRAS is linked to cancer.